GlassScriptPhysician profile
Belinda Graham
NPI 1770786915
$94,342.67
in general payments reported to CMS, 2019-2025
35 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,426 · 2020: $8,608 · 2021: $1,037 · 2022: $7,424 · 2023: $35K · 2024: $20K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $12K · Consulting Fee: $11K · Travel and Lodging: $8,639 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,840.05 |
| Food and Beverage | $11,620.79 |
| Consulting Fee | $10,594.00 |
| Travel and Lodging | $8,638.98 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $58,254.98 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $13,866.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $6,934.78 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech, INC. | $4,220.25 | 2023-2024 | Xolair |
| Genzyme Corporation | $2,768.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,741.05 | 2019-2025 | |
| Optinose US, INC. | $931.83 | 2019-2025 | |
| Amgen INC. | $902.33 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $717.88 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Blueprint Medicines Corporation | $392.76 | 2024-2025 | Ayvakit |
| Covis Pharma Gmbh | $344.00 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $343.98 | 2021-2025 | Orladeyo |
| Pfizer INC. | $259.89 | 2019-2025 | |
| Pharming Healthcare, INC. | $254.08 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $232.86 | 2019-2025 | Xolair |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $180.83 | 2024-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $153.99 | 2023-2025 | |
| Kaleo, INC. | $147.05 | 2019-2023 | Auvi-Q |
| Csl Behring | $142.87 | 2019-2025 | Hizentra, Haegarda |
| Teva Pharmaceuticals USA, INC. | $105.28 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $86.11 | 2025 | Neffy |
| Alk-Abello, INC | $50.50 | 2022 | |
| Phadia US INC. | $44.00 | 2019-2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.66 | 2020 | |
| Abbott Laboratories | $30.05 | 2023 | |
| Galderma Laboratories, L.P. | $25.09 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $23.78 | 2020 | |
| Azurity Pharmaceuticals, INC. | $22.98 | 2025 | Alvesco |
| Arcutis Biotherapeutics, INC. | $22.13 | 2024 | Zoryve |
| Lilly USA, LLC | $20.38 | 2025 | Ebglyss, Zepbound |
| Shire North American Group INC | $19.86 | 2019 | |
| Incyte Corporation | $18.93 | 2023 | Opzelura |
| Greer Laboratories, INC. | $18.72 | 2024 | Oralair |
| Merck Sharp & Dohme LLC | $15.32 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $12.86 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belinda Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.